Identify current and emerging approaches to early detection, screening, and prevention of hereditary breast, ovarian, pancreatic, and prostate cancers associated with mutations in the BRCA pathway.
Recognize and analyze the latest clinical and translational discoveries in the treatment of breast, ovarian, pancreatic, and prostate cancers associated with hereditary or acquired mutations in BRCA1/2 and related genes.
Discuss current ethical, legal, social as well as diversity and inclusion issues related to carriers of BRCA1/2 and related genes.
